LMTK2 and PARP-2 gene polymorphism and azoospermia secondary to meiotic arrest

Naoko Sakugawa1, Toshinobu Miyamoto, Akira Tsujimura

  • 1Department of Obstetrics and Gynecology, Asahikawa Medical College, Midorigaokahigashi2-1-1-1, Asahikawa, Hokkaido, Japan.

Abstract

Insights

Genetic analysis suggests the Poly(ADP-ribose) polymerase 2 (PARP-2) gene may be linked to azoospermia, a condition causing infertility due to meiotic arrest in sperm production.

Area of Science:

  • Genetics
  • Reproductive Biology
  • Molecular Biology

Background:

  • Azoospermia, characterized by the absence of sperm, can result from meiotic arrest.
  • Identifying genetic factors contributing to azoospermia is crucial for understanding male infertility.

Purpose of the Study:

  • To investigate potential associations between defects in the human LMTK2 and PARP-2 genes and azoospermia.
  • To determine if these gene defects contribute to infertility through meiotic arrest.

Main Methods:

  • Mutational analysis was conducted on the exon regions of LMTK2 and PARP-2 genes.
  • Genomic DNA from 18 Japanese men with azoospermia and normal controls was analyzed using direct sequencing.
  • Single nucleotide polymorphisms (SNPs) were identified and statistically analyzed.

Main Results:

  • Nine SNPs were identified in LMTK2 and five in PARP-2.
  • No significant differences in LMTK2 genotype or allele frequencies were found between patient and control groups.
  • A higher frequency of heterozygotes for SNP1 in PARP-2 was observed in the azoospermia patient group.
  • Haplotype analysis indicated that the PARP-2 SNP1-SNP4 (T-A) haplotype was significantly more common in patients.

Conclusions:

  • The findings suggest a potential association between the PARP-2 gene and azoospermia.
  • PARP-2 gene variations may play a role in the development of azoospermia through meiotic arrest.

Related Concept Videos

Meiosis II02:02

Meiosis II

Meiosis II entails cell division and segregation of the sister chromatids, resulting in the production of four unique haploid gametes. The steps for meiosis II are similar to mitosis, except that meiosis II occurs in haploid cells, whereas mitosis occurs in diploid cells.
The timing and cell division patterns of meiosis differ between males and females. In male meiosis, the centrosomes are part of the formation of the meiotic spindle. However, in oocytes, including that of humans, Drosophila,...
Meiosis II01:57

Meiosis II

Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each containing...
Meiosis I03:09

Meiosis I

Meiosis is the division of a diploid cell into haploid cells forming sperm and eggs in animals through differentiation. Meiosis I is the first stage of meiosis, where the genetic recombination of homologous chromosomes and the reduction of the ploidy level by half occurs.
Prophase I is the most extended and complex step of meiosis I characterized by synapsis, chromosome pairing, and recombination of the homologous chromosomes. This process is facilitated by a proteinaceous structure called the...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...